MPMi-Hyun Park

Mi-Hyun Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mi-Hyun Park has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Hyun-Young Park

    National Institute of Health, Cheongju, Republic of Korea

    5 shared publications
  • Bo-Young Kim

    Division of Intractable Diseases, National Center for Stem Cell and Regenerative Medicine, Center for Biomedical Sciences, Korea National Institute of Health, Korea Centers for Disease Control and Prevention, Cheongju-si, South Korea

    4 shared publications
  • Dong Mun Shin

    Division of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju, Republic of Korea

    4 shared publications
  • Hye-Won Cho

    Division of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju, Korea

    4 shared publications
  • Jeong-Min Kim

    Division of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju, Korea

    4 shared publications
  • Oc-Hee Kim

    Division of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju, Republic of Korea

    4 shared publications

Latest Publications

  • Open Access

    Accelerating genetic diagnosis in the NICU: neonatologist-driven rapid whole genome sequencing

    by Hye-Won Cho, Jeong-Min Kim, Sung Hyeon Park, Hyeseon Kim, Dong Mun Shin, Ho-Yeong Yu, Misun Yang, So Yoon Ahn, Se In Sung, Bong-Jo Kim, et al.

    To establish a rapid whole-genome sequencing (rWGS) workflow applicable to the neonatal intensive care unit (NICU) setting and evaluate its diagnostic utility and clinical feasibility. Twenty critically ill neonates with suspected genetic disorders were included in this study. A workflow for rWGS encompassing neonate enrollment through to the return of genetic diagnosis results was established. A trio-based rWGS data analysis was performed using DRAGEN-GATK-Hail, with results reviewed and reported by a multidisciplinary team. The average turnaround time for the 20 NICU neonates was 5.5 working days. Genetic diagnoses were achieved in ten cases, resulting in a diagnostic yield of 50%, based on the clinical database and variant pathogenicity assessments. The identified diagnostic variants were located across nine genes, including AGT, ANK1, NSD1, SERPINC1, OTC (in two cases), INS, PKHD1, SAMD9, and LZTR1. The clinical implications were confirmed in all ten diagnosed neonates, with 'genetic counseling and recurrence risk management', 'early therapeutic decision-making' and 'enhancement of clinical outcomes and survival rates'. Notably, neonate rWGS-03 demonstrated the highest impact, as rWGS enabled the early identification of renal tubular dysgenesis before symptom onset. This study demonstrates the feasibility of rWGS for critically ill neonates with suspected genetic disorders admitted to the NICU. As the first implementation of neonatologist-driven rWGS in Korea, it highlights the meaningful clinical benefits of timely and accurate diagnosis. Our findings underscore its clinical value and support the integration of rWGS into routine clinical care, as well as the development of future studies within public healthcare systems.

  • Open Access

    Unraveling the cellular characteristics of cardiomyopathy with rare variant-driven gene signatures using multi-omics analysis

    by Ha-Eun Jeong, Kyung-Hyun Kim, Youngjun Kim, Ho-Yeong Yu, Dong Mun Shin, Oc-Hee Kim, Bong-Jo Kim, Mi-Hyun Park, Jihyun Kim

    Whole-genome sequencing technologies have advanced, leading to an increase in uncharacterized variants with unknown functions. This study focuses on characterizing cardiomyopathy-associated genes harboring theses rare variants and uncovering their cellular contexts using single-cell transcriptomics. We investigated whole genome sequencing on 245 unrelated Korean patients with either dilated (48.2%) and hypertrophic (47.8%) cardiomyopathy. Rare variants were identified and subjected to burden analysis to detect potentially causative candidates. To understand their biological impact, we profiled single-cell transcriptomes from an independent dataset, highlighting cell populations and interactions relevant to disease pathogenesis. A total of 3584 rare variants were discovered, including 50 pathogenic or likely pathogenic variants in 41 patients. Among the remaining 3534 variants of uncertain significance (VUS), burden analysis revealed 144 gene signatures significantly enriched in pathways related to cardiac muscle tissue development, heart morphogenesis, and endocrine system development (FDR < 0.003). These gene signatures were strongly correlated with cardiomyopathy − associated phenotypes, including HCM (HP:0001639) and DCM (HP:0001644) from the Human Phenotype Ontology (HPO) database. Single-cell transcriptomic analysis of 11,664 heart tissue cells demonstrated that the expression of these gene is influenced by cellular heterogeneity, which may contribute to disease manifestation. Further analysis identified five major cell types in heart tissue, revealing dynamic interactions between cardiomyocytes and endothelial cells. Rare genetic variants, including VUS, are closely linked to cardiac developmental processes and the sarcolemma integrity in cardiomyopathy. Our findings underscore the critical involvement of both cardiomyocytes and non-cardiomyocytes in disease etiology, highlighting the utility of integrating genomic and single-cell data for mechanistic insights.


  • Open Access

    Clinical implementation of a multidisciplinary pipeline for genome sequencing in rare diseases: A prospective, multicenter, observational cohort study

    by Soojin Hwang, Go Hun Seo, In Hee Choi, Seung‐Woo Ryue, Ji Young Oh, Yoo‐Mi Kim, Baik‐Lin Eun, Jung Hye Byeon, Eugu Kang, Myungshin Kim, et al.


  • Open Access

    Identification of novel MYO19 variants in neonatal hypertrophic cardiomyopathy: a familial analysis revealing oligogenic contributors to disease severity

    by Hye-Won Cho, Hyeseon Kim, Jeong-Min Kim, Dong Mun Shin, Oc-Hee Kim, Misun Yang, Heui Seung Jo, Mi-Ae Jang, Ja-Hyun Jang, Hyun-Young Park, et al.

    Background: Pediatric hypertrophic cardiomyopathy (HCM) is a rare condition, particularly in neonates, and is characterized by rapid and extensive myocardial hypertrophy, often leading to severe clinical outcomes. HCM can arise from variants in sarcomeric genes, which are essential for myocardial contractions, as well as non-sarcomeric gene variants. Although genetic modifiers and oligogenic inheritance have been implicated in congenital heart disease and cardiomyopathy, their complexity in HCM has not been fully elucidated, especially in familial cases with variable phenotypes. Hence, this study aims to investigate the genetic architecture in a family with a history of cardiac disease and neonatal HCM, focusing on oligogenic inheritance of non-sarcomeric variants. Methods: Clinical data and blood samples were collected for genetic analysis. Whole genome sequencing (WGS) and bioinformatic analyses identified compound heterozygous variants in the MYO19 gene. Maternally inherited variants were analyzed because the proband’s mother was also diagnosed with HCM. WGS was performed on the patient’s maternal grandfather and aunt, who have cardiac disease, revealing candidate genetic variants that may contribute to the cardiac phenotype. Results: Compound heterozygous MYO19 variants were identified in the neonatal patient. Missense c.203C > G (p.A68G) and frameshift c.275_276del (p.E92Vfs*19) variants were identified, which were located in the myosin motor domain, a functionally crucial region of the MYO19 protein. Maternally inherited missense variants were identified in SURF1 and ETFDH. All three genes are associated with mitochondrial function, and in silico prediction tools suggest that these variants are likely damaging. Other candidate genetic variants possibly contributing to the cardiac phenotype were also detected in the extended maternal family. Conclusions: To the best of our knowledge, this study represents the first report proposing MYO19 as a candidate gene for HCM and highlights the potential role of oligogenic inheritance in the etiology of the disease. Furthermore, plausible candidate variants of other mitochondria-related genes, such as MYO19, SURF1, and ETFDH, were identified, and other family members were investigated to support the pathogenesis of HCM further. Given the limited understanding of the genetics of pediatric HCM, these findings contribute valuable insights into its genetic basis in pediatric patients.

  • Open Access

    Two novel genetic variants in the WFDC2 gene from patients with bronchiectasis

    by Jeong-Min Kim, Soojin Hwang, Hye-Won Cho, Youngjun Kim, Dong Mun Shin, Eun Lee, Myungshin Kim, Cheonghwa Lee, Jong-Won Kim, Hyun-Young Park, et al.

    Bronchiectasis is a chronic respiratory condition characterized by irreversible dilation and damage of the bronchial walls, leading to impaired mucociliary clearance and recurrent infections. Its etiology is diverse; however, genetic factors are critical in its congenital and severe forms. Therefore, we aimed to identify two novel variants of the WFDC2 gene, known as antiprotease, from patients with bronchiectasis and/or related phenotypes using trio-based whole-genome sequencing analysis. Patients with bronchiectasis were recruited as trio or quad, and their genomic DNA was isolated. The whole genome sequence was produced and analyzed to find causative genetic variants through an internal pipeline using GATK-DRAGEN-Hail. Variant interpretation and pathogenicity assessment using various in-silico tools were performed to identify causative variants. Clinical characteristics were collected from the patients with identified variants. In this discovery study involving four patients from three families, two novel variants in the WFDC2 gene were identified and suggested as causative pathogenic variants for bronchiectasis. The first variant (c.291 C > G, p.(Cys97Trp)) is a homozygous variant that was not found in the population genome data. However, the second variant (c.278G > C, p.(Cys93Ser)) was identified in another patient as a heterozygous variant, forming a compound heterozygous state with the first variant. Notably, both variants, located at cysteine residues that are conserved across many species, are crucial in forming disulfide bonds essential for protein structure and function. In-silico analyses classified both variants as pathogenic; they were also identified as likely pathogenic according to the American College of Medical Genetics and Genomic guidelines. Furthermore, in an expansion study, the homozygous variant was also found in two unrelated patients. We identified two novel bi-allelic variants located at cysteine residues in the WFDC2 gene from patients with bronchiectasis who had previously not received a genetic diagnosis. Therefore, considering prior research on the pivotal role of the WFDC2 protein in the respiratory system, these two novel variants may serve as potential diagnostic markers and therapeutic targets for bronchiectasis. Not Applicable.


  • Open Access

    Uncovering potential causal genes for undiagnosed congenital anomalies using an in-house pipeline for trio-based whole-genome sequencing

    by Jeong-Min Kim, Hye-Won Cho, Dong Mun Shin, Oc-Hee Kim, Jihyun Kim, Hyeji Lee, Gang-Hee Lee, Joon-Yong An, Misun Yang, Heui Seung Jo, et al.

    Congenital anomalies (CAs) encompass a wide spectrum of structural and functional abnormalities during fetal development, commonly presenting at birth. Identifying the cause of CA is essential for accurate diagnosis and treatment. Using a target-gene approach, genetic variants could be found in certain CA patients. However, some patients were genetically undiagnosed; therefore, it is imperative to identify the causative variants from whole genome sequence (WGS) data of these patients. An in-house pipeline utilizing DRAGEN-GATK-Hail was established for trio-based WGS data analysis (n = 18 undiagnosed CA patients and their parents) and thirty-five candidate variants, including SNV/Indel, CNV, and SV were identified. Among them, 10 variants of seven coding genes were selected as possible causal variants by variant pathogenicity, genotype–phenotype analysis, and a multidisciplinary team. Finally, functional validation of six genes including RYR3, NRXN1, FREM2, CSMD1, RARS1, and NOTCH1, revealed various phenotypes in zebrafish models that aligned with those observed in each patient. In addition to the above findings, eleven diagnostic variants initially discovered in a targeted-gene analysis from a previous study were also identified as diagnostic variants and the in-house pipeline demonstrated a significant advantage in accurately and efficiently identifying de novo variants (DNVs), compound heterozygous (CH), and homozygous variants. Taken together, the in-house pipeline established in this study provides a highly valuable diagnostic tool for the identification of potential candidate variants in patients with CA. Further research into the molecular mechanisms related to the development of CAs could shed light on the functional aspects of these genetic variations and contribute to the development of therapeutic drugs.


  • Open Access

    Exploring novel MYH7 gene variants using in silico analyses in Korean patients with cardiomyopathy

    by Oc-Hee Kim, Jihyun Kim, Youngjun Kim, Soyoung Lee, Beom Hee Lee, Bong-Jo Kim, Hyun-Young Park, Mi-Hyun Park

    Pathogenic variants of MYH7, which encodes the beta-myosin heavy chain protein, are major causes of dilated and hypertrophic cardiomyopathy. In this study, we used whole-genome sequencing data to identify MYH7 variants in 397 patients with various cardiomyopathy subtypes who were participating in the National Project of Bio Big Data pilot study in Korea. We also performed in silico analyses to predict the pathogenicity of the novel variants, comparing them to known pathogenic missense variants. We identified 27 MYH7 variants in 41 unrelated patients with cardiomyopathy, consisting of 20 previously known pathogenic/likely pathogenic variants, 2 variants of uncertain significance, and 5 novel variants. Notably, the pathogenic variants predominantly clustered within the myosin motor domain of MYH7. We confirmed that the novel identified variants could be pathogenic, as indicated by high prediction scores in the in silico analyses, including SIFT, Mutation Assessor, PROVEAN, PolyPhen-2, CADD, REVEL, MetaLR, MetaRNN, and MetaSVM. Furthermore, we assessed their damaging effects on protein dynamics and stability using DynaMut2 and Missense3D tools. Overall, our study identified the distribution of MYH7 variants among patients with cardiomyopathy in Korea, offering new insights for improved diagnosis by enriching the data on the pathogenicity of novel variants using in silico tools and evaluating the function and structural stability of the MYH7 protein.


  • Open Access

    Diagnostic Utility of Whole Genome Sequencing After Negative Karyotyping/Chromosomal Microarray in Infants Born With Multiple Congenital Anomalies

    by Misun Yang, Jee Ah Kim, Heui Seung Jo, Jong-Ho Park, So Yoon Ahn, Se In Sung, Won Soon Park, Hye-Won Cho, Jeong-Min Kim, Mi-Hyun Park, et al.

    Yang M, et al. J Korean Med Sci. 2024 Aug;39:e250. https://doi.org/10.3346/jkms.2024.39.e250


  • Open Access

    Frequency of actionable secondary findings in 7472 Korean genomes derived from the National Project of Bio Big Data pilot study

    by Youngjun Kim, Jeong-Min Kim, Hye-Won Cho, Hyun-Young Park, Mi-Hyun Park

    Exome and genome sequencing (ES/GS) in genetic medicine and research leads to discovering genomic secondary findings (SFs) unrelated to the purpose of the primary test. There is a lack of agreement to return the SF results for individuals undergoing the test. The aim of this study is to investigate the frequency of actionable secondary findings using GS data obtained from the rare disease study and the Korean Genome and Epidemiology Study (KoGES) in the National Project of Bio Big Data pilot study. Pathogenic (P) or likely pathogenic (LP) variants of 78 SF genes recommended by the American College of Medical Genetics and Genomics (ACMG) were screened in the rare disease study and KoGES. The pathogenicity of SF gene variants was determined according to the ACMG interpretation. The overall SF rate was 3.75% for 280 individuals with 298 P/LP variants of 41 ACMG SF genes which were identified among 7472 study participants. The frequencies of genes associated with cardiovascular, cancer, and miscellaneous phenotypes were 2.17%, 1.22%, and 0.58%, respectively. The most frequent SF gene was TTN followed by BRCA2. The frequency of actionable SFs among participants with rare disease and general population participants in the Korean population presented here will assist in reporting results of medically actionable SFs in genomic medicine.